The FDA has delayed granting full approval of Novavax's COVID-19 vaccine despite it being on track to be cleared until ...

The US drug regulator has missed a deadline for granting full approval to Novavax's COVID-19 vaccine, the company said ...

BioNTech (NASDAQ:BNTX – Get Free Report) had its target price dropped by analysts at HC Wainwright from $150.00 to $145.00 in ...

The US drug regulator has missed a deadline for granting full approval to Novavax's Covid-19 vaccine, the company said on ...

We recently published a list of 12 Best German Stocks to Buy According to Hedge Funds. In this article, we are going to take ...

It comes on the heels of the FDA's top vaccine scientist Peter Marks' exit from the agency, which will be effective April 5.

The U.S. Food and Drug Administration has missed its deadline for making a decision on traditional approval for Novavax's ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $152.57, a high ...

H.C. Wainwright lowered the firm’s price target on BioNTech (BNTX) to $145 from $150 and keeps a Buy rating on the shares. The firm says ...

BioNTech SE (NASDAQ:BNTX – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the eighteen brokerages that are covering the company, MarketBeat.com reports. Three research ...

Truist Financial analyst Asthika Goonewardene maintained a Buy rating on BioNTech SE (BNTX – Research Report) today. The company’s shares ...

Shares of CureVac climbed after the European Patent Office confirmed the validity of a patent that has been the subject of a lawsuit filed by BioNTech. The stock rose 7% to $2.99 on Friday. Shares ...